GlassScriptPhysician profile
Landrum Irvin Mccarrell
NPI 1316975758
$5,792.44
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $449 · 2021: $643 · 2022: $1,397 · 2023: $1,459 · 2024: $96.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $742.26 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $537.54 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $432.59 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $382.95 | 2019-2023 | Farxiga |
| Pfizer INC. | $377.20 | 2019-2023 | |
| Lilly USA, LLC | $358.43 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $329.01 | 2019-2023 | Otezla, Repatha, Aimovig |
| Glaxosmithkline, LLC. | $318.92 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.43 | 2019-2023 | Tradjenta, Synjardy, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.72 | 2019-2024 | Xifaxan |
| Dexcom, INC. | $167.43 | 2022-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $161.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.77 | 2021-2023 | |
| Abbott Laboratories | $129.59 | 2019-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $124.14 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landrum Mccarrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.